Tamsulosin Hydrochloride Capsule
Product Images NDC 67296-2220

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 67296-2220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tamsulosin Fig1)

A line graph showing mean plasma tamsulosin hydrochloride concentrations (ng/mL) over time (hours) following a single 0.4 mg capsule dose under fasted and fed conditions. The graph plots two curves: one for fasted (dashed line) and one for fed (solid line) states, depicting plasma concentration changes up to 36 hours post-dose.*

FDA Label Image

Figure (Tamsulosin Fig2)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean symptom score changes over duration of treatment in weeks. It compares three treatments: 0.8 mg, 0.4 mg of Tamsulosin Hydrochloride, and placebo. The vertical axis represents mean change, and the horizontal axis represents treatment duration from baseline to 13 weeks and LOCF. Sample sizes at each time point are included.*

FDA Label Image

Figure (Tamsulosin Fig3)

Line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2,' showing mean change on the vertical axis and duration of treatment in weeks on the horizontal axis. It compares three treatments: 0.8 mg, 0.4 mg, and placebo, with data points plotted at various weeks. The graph includes sample sizes at each time point and a legend identifying each treatment group by line style and markers.*

FDA Label Image

Figure (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in urine flow rate over a treatment duration of up to 13 weeks. It compares three groups: Tamsulosin Hydrochloride 0.8 mg, 0.4 mg, and placebo. Both doses show a marked increase in urine flow rate over time, while the placebo remains near baseline.*

FDA Label Image

Figure (Tamsulosin Fig5)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing the mean change in flow rate over weeks of treatment. The x-axis represents duration of treatment in weeks, while the y-axis shows mean change in L/sec. Three treatment groups are compared: 0.8 mg, 0.4 mg, and placebo, with 0.8 mg showing the highest increase followed by 0.4 mg and placebo over the study period.*

FDA Label Image

Package Label-principal Display Panel (0.4 mg (100 Capsules Bottle))

Label for Tamsulosin Hydrochloride Capsules USP 0.4 mg, in a package of 100 capsules by Redpharm Drug. The label includes storage instructions, manufacturing information, and a barcode. The label states the product is made in India, with a note on coding area for GTIN, serial number, expiry date, and lot to be printed during packing.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride, showing its molecular components and arrangement, including aromatic rings, oxygen, sulfur, nitrogen atoms, and the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.